Douglas Tsao
Stock Analyst at H.C. Wainwright
(4.91)
# 251
Out of 5,118 analysts
1169
Total ratings
52.9%
Success rate
22.1%
Average return
Main Sectors:
Stocks Rated by Douglas Tsao
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AGIO Agios Pharmaceuticals | Reiterated: Buy | $55 → $62 | $29.41 | +110.81% | 3 | Nov 6, 2026 | |
| CABA Cabaletta Bio | Reiterated: Buy | $16 | $1.30 | +1,130.77% | 53 | Nov 6, 2026 | |
| IRON Disc Medicine | Reiterated: Buy | $120 → $127 | $78.91 | +60.94% | 44 | Nov 6, 2026 | |
| PTGX Protagonist Therapeutics | Reiterated: Buy | $170 → $221 | $132.04 | +67.37% | 81 | Nov 6, 2026 | |
| RZLT Rezolute | Reiterated: Buy | $10 | $3.88 | +157.73% | 51 | Nov 6, 2026 | |
| ARQT Arcutis Biotherapeutics | Reiterated: Buy | $34 → $40 | $25.55 | +56.56% | 21 | Nov 5, 2026 | |
| EOLS Evolus | Reiterated: Buy | $13 | $6.81 | +91.04% | 58 | Nov 5, 2026 | |
| RAPP Rapport Therapeutics | Rated: Buy | $66 → $63 | $24.44 | +157.77% | 16 | Nov 5, 2026 | |
| VRDN Viridian Therapeutics | Reiterated: Buy | $22 → $40 | $28.49 | +40.40% | 32 | Nov 5, 2026 | |
| ALKS Alkermes | Reiterated: Hold | $43 → $50 | $45.90 | +8.93% | 62 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | ILA 17,031 | ILA 13,300 | +28.05% | 1 | Nov 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $10 | $14.48 | -30.94% | 25 | Nov 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $74 | $39.17 | +88.92% | 19 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,202 → $1,291 | $927.21 | +39.23% | 71 | Oct 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $47 | $38.88 | +20.88% | 49 | Oct 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $1,201 | $277.62 | +332.61% | 59 | Oct 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $38 → $37 | $36.43 | +0.19% | 31 | Oct 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $41 | $30.53 | +34.29% | 47 | Sep 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.77 | +809.09% | 79 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $12 | $0.639 | +1,777.93% | 42 | Sep 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $0.5033 | +1,290.82% | 26 | Aug 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $360 → $1.2 | $0.1759 | +582.21% | 10 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $2.42 | +189.26% | 44 | Aug 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $0.5 → $1.6 | $0.4364 | +266.64% | 48 | Jul 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | kr 103.00 | kr 39.46 | +161.02% | 52 | Jul 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7 | $1.69 | n/a | 13 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $125 → $5 | $0.0111 | n/a | 26 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $6 | $10.29 | n/a | 4 | Mar 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.74 | n/a | 19 | Nov 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €19.00 → €11.00 | €2.75 | n/a | 7 | Nov 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $31 → $33 | $32.96 | n/a | 2 | Jul 3, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $93 → $80 | $15.85 | n/a | 8 | Jun 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $40.93 | $11.56 | n/a | 17 | Jun 6, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $20.14 | n/a | 2 | May 1, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $71 → $77 | $79.40 | n/a | 6 | Feb 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $108 → $120 | $204.74 | n/a | 12 | Oct 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $100 → $120 | $271.83 | n/a | 3 | Oct 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $16 | $103.63 | n/a | 3 | Jun 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $47 → $50 | $19.91 | n/a | 6 | May 22, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $200 | $234.76 | n/a | 7 | Jan 18, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $337.52 | n/a | 5 | Nov 30, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $14 → $2 | $10.35 | n/a | 5 | Nov 16, 2016 |
Agios Pharmaceuticals
Nov 6, 2026
Reiterated: Buy
Price Target: $55 → $62
Current: $29.41
Upside: +110.81%
Cabaletta Bio
Nov 6, 2026
Reiterated: Buy
Price Target: $16
Current: $1.30
Upside: +1,130.77%
Disc Medicine
Nov 6, 2026
Reiterated: Buy
Price Target: $120 → $127
Current: $78.91
Upside: +60.94%
Protagonist Therapeutics
Nov 6, 2026
Reiterated: Buy
Price Target: $170 → $221
Current: $132.04
Upside: +67.37%
Rezolute
Nov 6, 2026
Reiterated: Buy
Price Target: $10
Current: $3.88
Upside: +157.73%
Arcutis Biotherapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $34 → $40
Current: $25.55
Upside: +56.56%
Evolus
Nov 5, 2026
Reiterated: Buy
Price Target: $13
Current: $6.81
Upside: +91.04%
Rapport Therapeutics
Nov 5, 2026
Rated: Buy
Price Target: $66 → $63
Current: $24.44
Upside: +157.77%
Viridian Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $22 → $40
Current: $28.49
Upside: +40.40%
Alkermes
Nov 4, 2026
Reiterated: Hold
Price Target: $43 → $50
Current: $45.90
Upside: +8.93%
Nov 4, 2026
Reiterated: Buy
Price Target: ILA 17,031
Current: ILA 13,300
Upside: +28.05%
Nov 2, 2026
Reiterated: Hold
Price Target: $10
Current: $14.48
Upside: -30.94%
Oct 29, 2026
Reiterated: Buy
Price Target: $74
Current: $39.17
Upside: +88.92%
Oct 23, 2026
Reiterated: Buy
Price Target: $1,202 → $1,291
Current: $927.21
Upside: +39.23%
Oct 21, 2026
Reiterated: Buy
Price Target: $47
Current: $38.88
Upside: +20.88%
Oct 15, 2026
Reiterated: Buy
Price Target: $1,201
Current: $277.62
Upside: +332.61%
Oct 9, 2026
Downgraded: Hold
Price Target: $38 → $37
Current: $36.43
Upside: +0.19%
Sep 23, 2026
Reiterated: Buy
Price Target: $41
Current: $30.53
Upside: +34.29%
Sep 21, 2026
Reiterated: Buy
Price Target: $7
Current: $0.77
Upside: +809.09%
Sep 21, 2026
Reiterated: Buy
Price Target: $12
Current: $0.639
Upside: +1,777.93%
Aug 24, 2026
Reiterated: Buy
Price Target: $7
Current: $0.5033
Upside: +1,290.82%
Aug 14, 2026
Reiterated: Buy
Price Target: $360 → $1.2
Current: $0.1759
Upside: +582.21%
Aug 10, 2026
Reiterated: Hold
Price Target: $7
Current: $2.42
Upside: +189.26%
Jul 28, 2026
Rated: Hold
Price Target: $0.5 → $1.6
Current: $0.4364
Upside: +266.64%
Jul 24, 2026
Reiterated: Buy
Price Target: kr 103.00
Current: kr 39.46
Upside: +161.02%
Nov 6, 2025
Reiterated: Buy
Price Target: $7
Current: $1.69
Upside: n/a
Nov 14, 2024
Downgraded: Hold
Price Target: $125 → $5
Current: $0.0111
Upside: n/a
Mar 8, 2023
Reiterated: Hold
Price Target: $6
Current: $10.29
Upside: n/a
Nov 30, 2022
Rated: Hold
Price Target: n/a
Current: $1.74
Upside: n/a
Nov 1, 2022
Reiterated: Buy
Price Target: €19.00 → €11.00
Current: €2.75
Upside: n/a
Jul 3, 2018
Reiterated: Sell
Price Target: $31 → $33
Current: $32.96
Upside: n/a
Jun 6, 2018
Downgraded: Hold
Price Target: $93 → $80
Current: $15.85
Upside: n/a
Jun 6, 2018
Upgraded: Buy
Price Target: $40.93
Current: $11.56
Upside: n/a
May 1, 2018
Initiated Coverage: Buy
Price Target: $27
Current: $20.14
Upside: n/a
Feb 16, 2018
Reiterated: Hold
Price Target: $71 → $77
Current: $79.40
Upside: n/a
Oct 27, 2017
Reiterated: Hold
Price Target: $108 → $120
Current: $204.74
Upside: n/a
Oct 27, 2017
Reiterated: Buy
Price Target: $100 → $120
Current: $271.83
Upside: n/a
Jun 22, 2017
Reiterated: Buy
Price Target: $16
Current: $103.63
Upside: n/a
May 22, 2017
Upgraded: Buy
Price Target: $47 → $50
Current: $19.91
Upside: n/a
Jan 18, 2017
Reiterated: Buy
Price Target: $200
Current: $234.76
Upside: n/a
Nov 30, 2016
Upgraded: Hold
Price Target: n/a
Current: $337.52
Upside: n/a
Nov 16, 2016
Reiterated: Sell
Price Target: $14 → $2
Current: $10.35
Upside: n/a